GlassScriptPhysician profile
James F Beekman
NPI 1043221013
$124,822.76
in general payments reported to CMS, 2019-2025
48 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,783 · 2021: $5,661 · 2022: $19K · 2023: $21K · 2024: $25K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $12K · Consulting Fee: $3,680 · Travel and Lodging: $1,566 · Education: $92.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,725.00 |
| Food and Beverage | $12,256.69 |
| Consulting Fee | $3,680.00 |
| Travel and Lodging | $1,566.17 |
| Education | $92.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102,728.30 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $9,822.41 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $2,722.01 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Janssen Biotech, INC. | $1,339.26 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $1,219.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $940.82 | 2019-2025 | |
| Lilly USA, LLC | $710.31 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $651.92 | 2019-2025 | Orencia |
| Glaxosmithkline, LLC. | $467.16 | 2019-2025 | Benlysta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $405.87 | 2022-2025 | Saphnelo |
| Genentech USA, INC. | $319.67 | 2019-2025 | Actemra, Gazyva |
| Mallinckrodt Hospital Products INC. | $297.18 | 2022-2025 | Acthar |
| Alexion Pharmaceuticals, INC. | $292.57 | 2019-2025 | Strensiq, Ultomiris, Soliris |
| Fresenius Kabi USA, LLC | $284.30 | 2023-2025 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.09 | 2022-2025 | Ofev, Cyltezo |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $261.82 | 2022-2025 | Renflexis, Hadlima, Nexplanon |
| Radius Health, INC. | $213.31 | 2019-2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $193.30 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $190.16 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $166.52 | 2019-2023 | Injectafer |
| Genzyme Corporation | $159.45 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $142.18 | 2022-2024 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $137.07 | 2019 | |
| Sobi, INC | $127.32 | 2024-2025 | |
| Sandoz INC. | $112.95 | 2023-2025 | Hyrimoz |
| Celgene Corporation | $72.48 | 2019-2024 | Orencia |
| Kiniksa Pharmaceuticals International, Plc | $69.83 | 2024 | Arcalyst |
| Octapharma USA, INC. | $58.83 | 2023-2024 | Octagam Immune Globulin (Human) |
| Scilex Pharmaceuticals INC. | $46.65 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $45.25 | 2023 | Uptravi, Opsumit |
| Mylan Institutional INC. | $41.13 | 2023 | Hulio |
| Mallinckrodt Enterprises LLC | $38.09 | 2019 | |
| Pharmacosmos Therapeutics INC. | $33.55 | 2022-2023 | Monoferric |
| Abbott Laboratories | $28.93 | 2025 | Eterna |
| Medexus Pharma, INC. | $28.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.36 | 2023 | Seglentis |
| Zimmer Biomet Holdings, INC. | $24.49 | 2022 | |
| Boston Scientific Corporation | $24.32 | 2019 | |
| Celltrion USA INC. | $18.86 | 2023 | Yuflyma |
| Novo Nordisk INC | $16.60 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $16.15 | 2022 | |
| Hikma Pharmaceuticals USA | $15.66 | 2019 | |
| Medtronic, INC. | $13.62 | 2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| United Therapeutics Corporation | $7.50 | 2021 | |
| Hospira, INC. | $2.99 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Beekman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.